Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)

March 25, 2018

Responsive image

LÖRRACH, Germany and SAINT LOUIS, France, March 26, 2018 /PRNewswire/ — Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drug resistant bacterial infections, today announced positive top-line results from the Phase 2…

Category: Precious Metals